AHCO — AdaptHealth Corp.

Summary of AdaptHealth Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Revenue: $740.3 million, up 12.7% year-over-year and 15.9% on an organic basis.
• Adjusted EBITDA: $132 million, with an adjusted EBITDA margin of 17.8%, down from $136.4 million in the prior year.
• Capitated Revenue: Grew to $103.3 million, representing approximately 14% of net revenue from continuing operations.
• Free Cash Flow: Negative $20.9 million for the quarter, primarily due to $166.2 million in capital expenditures.
• Consolidated Total Leverage Ratio: 3.06x.
• Goodwill Impairment: $144.2 million due to the reallocation of overhead costs following the divestiture of the Diabetes Health segment.

2. Strategic Updates and Business Highlights

• Organic Growth: Achieved 16% organic growth with record volume gains.
• Portfolio Restructuring: Announced the sale of the Diabetes Health business for $235 million and exited non-core products within Wellness-at-Home.
• Joint Venture: Created a joint venture for the CPAP Shop to enhance direct-to-consumer capabilities.
• Capitated Agreements: Expanded relationships, including a new agreement with Humana covering 33 states and the District of Columbia.

3. Forward Guidance and Outlook

• Full Year 2026 Revenue Guidance: Projected between $2.85 billion and $2.89 billion, reflecting a slight increase from prior guidance.
• Adjusted EBITDA Guidance: Revised to $490 million to $520 million, down from previous expectations of $680 million to $730 million.
• Free Cash Flow Projection: Expected to be between $80 million and $120 million for the full year.
• Q3 2026 Expectations: Net revenue projected at $720 million to $740 million, with an adjusted EBITDA margin of approximately 17.9%.

4. Bad News, Challenges, or Points of Concern

• West Coast Capitated Contract: Faced operational challenges leading to a $15 million miss in expected revenue and an anticipated $40 million impact on profitability for the second half of the year.
• Manufacturer Price Increase: A significant price increase from a major supplier effective July 1, resulting in a $30 million impact on the second half of 2026.
• Negative Free Cash Flow: Reflects ongoing capital expenditures and operational challenges.
• Goodwill Impairment: Indicates potential issues with prior acquisitions and portfolio management.

5. Notable Q&A Insights

• Capitated Contracts: Management remains committed to a mix of capitated and fee-for-service models, citing long-term benefits despite current operational challenges.
• Operational Adjustments: Emphasis on streamlining workflows and improving logistics to address inefficiencies in the West Coast contract.
• Divestiture Strategy: The decision to divest non-core assets is aimed at focusing on higher-margin segments, with expectations of improved profitability in the long term.
• Cybersecurity Incident: A recent cybersecurity threat was resolved without ongoing risk, with associated costs included in nonrecurring expenses.

Overall, while AdaptHealth reported solid revenue growth and strategic advancements, it faces significant challenges related to operational execution, supplier pricing pressures, and restructuring impacts that may affect short-term profitability.